Multimodal Oncological Therapy Comprising Stents, Brachytherapy and Regional Chemotherapy for Cholangiocarcinoma
| Autoři | |
|---|---|
| Rok publikování | 2010 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Gut and Liver |
| Fakulta / Pracoviště MU | |
| Citace | |
| Doi | http://dx.doi.org/10.5009/gnl.2010.4.S1.S82 |
| Obor | Ostatní lékařské obory |
| Klíčová slova | Cholangiocarcinoma; Brachytherapy; Infusions; Intra-arterial; Stents |
| Popis | BACKGROUND/AIMS: To prospectively evaluate our palliative management of unresectable cholangiocarcinoma (CC) treated with tailored multimodal oncological therapy. In total, 78 metal self-expandable stents were placed. Hilar involvement with mass-forming and periductal infiltrating types of CC (84%) was predominant. The average number of percutaneous interventional procedures was 11.61 per patient (range, 4-35). The median overall survival from diagnosis of disease for all patients was 13.5 months . The median overall survival times were 25.2 months and 11.5 months in the IA and IV arms, respectively (p<0.05). The 1-, 2-, and 3-year survival rates in the IA and IV arms were 88.2%, 52.9%, and 10.1% and 43.5%, 25.4, and 0%, respectively.CONCLUSIONS: We could reach acceptable prognosis in patients with unresectable CC using complex tailored oncological therapy. However, the main limitations of prolonging survival are performance status, patient compliance and the maintaining of biliary tract patency. |